These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Morrissey I; Olesky M; Hawser S; Lob SH; Karlowsky JA; Corey GR; Bassetti M; Fyfe C Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31843999 [TBL] [Abstract][Full Text] [Related]
4. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial. Vega S; Dowzicky MJ Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170 [TBL] [Abstract][Full Text] [Related]
5. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study. Karlowsky JA; Adam HJ; Baxter MR; Lagacé-Wiens PR; Walkty AJ; Hoban DJ; Zhanel GG Antimicrob Agents Chemother; 2013 Nov; 57(11):5600-11. PubMed ID: 23979759 [TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Sader HS; Jones RN; Dowzicky MJ; Fritsche TR Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565 [TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial. Morfin-Otero R; Noriega ER; Dowzicky MJ Ann Clin Microbiol Antimicrob; 2015 Dec; 14():53. PubMed ID: 26667651 [TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015). Pfaller MA; Flamm RK; Duncan LR; Streit JM; Castanheira M; Sader HS Diagn Microbiol Infect Dis; 2018 May; 91(1):77-84. PubMed ID: 29395713 [TBL] [Abstract][Full Text] [Related]
9. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003). Sader HS; Fritsche TR; Jones RN Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011. Kanj SS; Whitelaw A; Dowzicky MJ Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313 [TBL] [Abstract][Full Text] [Related]
11. Eravacycline, a newly approved fluorocycline. Lee YR; Burton CE Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1787-1794. PubMed ID: 31175478 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020. Hawser S; Kothari N; Monti F; Morrissey I; Siegert S; Hodges T J Glob Antimicrob Resist; 2023 Jun; 33():304-320. PubMed ID: 37207925 [TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in Taiwan: A clinical microbiological study. Tsai MH; Chen CL; Chang HJ; Chuang TC; Chiu CH J Glob Antimicrob Resist; 2024 Jun; 37():93-99. PubMed ID: 38552878 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ; Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561 [TBL] [Abstract][Full Text] [Related]
16. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Sader HS; Jones RN; Stilwell MG; Dowzicky MJ; Fritsche TR Diagn Microbiol Infect Dis; 2005 Jul; 52(3):181-6. PubMed ID: 16105562 [TBL] [Abstract][Full Text] [Related]
17. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Sutcliffe JA; O'Brien W; Fyfe C; Grossman TH Antimicrob Agents Chemother; 2013 Nov; 57(11):5548-58. PubMed ID: 23979750 [TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from Eastern Europe: Results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2011-2016. Dowzicky MJ; Chmelařová E J Glob Antimicrob Resist; 2019 Jun; 17():44-52. PubMed ID: 30445209 [TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205 [TBL] [Abstract][Full Text] [Related]
20. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]